Influence of the Eliminated Ligand Structure on the Reduction Rate of the Cobalt(III) Complexes
- Авторлар: Nikovskii I.A.1, Spiridonov K.A.1,2, Dan′shina A.A.1,3, Khakina E.A.1, Nelyubina Y.V.1
-
Мекемелер:
- Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
- Moscow State University
- Moscow Institute of Physics and Technology (National Research University)
- Шығарылым: Том 50, № 4 (2024)
- Беттер: 251-260
- Бөлім: Articles
- URL: https://genescells.com/0132-344X/article/view/667605
- DOI: https://doi.org/10.31857/S0132344X24040039
- EDN: https://elibrary.ru/NPVTSR
- ID: 667605
Дәйексөз келтіру
Аннотация
The reduction of the heteroleptic cobalt(III) complexes with bipyridine ligands of different structures of the model drug molecule is studied by in situ NMR spectroscopy. The nature of the ligand eliminated during reduction is shown to exert a substantial effect on the reduction rate, which indicates that an optimum amount of cobalt should be chosen for the redox-activated delivery of a certain drug.
Толық мәтін

Авторлар туралы
I. Nikovskii
Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
Email: khakina90@ineos.ac.ru
Ресей, Moscow
K. Spiridonov
Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences; Moscow State University
Email: khakina90@ineos.ac.ru
Ресей, Moscow; Moscow
A. Dan′shina
Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences; Moscow Institute of Physics and Technology (National Research University)
Email: khakina90@ineos.ac.ru
Ресей, Moscow; Dolgoprudnyi
E. Khakina
Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
Хат алмасуға жауапты Автор.
Email: khakina90@ineos.ac.ru
Ресей, Moscow
Yu. Nelyubina
Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
Email: khakina90@ineos.ac.ru
Ресей, Moscow
Әдебиет тізімі
- Jungwirth, U., Kowol, C.R., Keppler, B.K., et al., Antioxid. Redox. Signaling, 2011, vol. 15, p. 1085.
- Brown, J.M. and Wilson, W.R., Nat. Rev. Cancer, 2004, vol. 4, p. 437.
- Denny, W.A., Cancer Invest., 2004, vol. 22, p. 604.
- Graf, N. and Lippard, S.J., Adv. Drug. Deliv. Rev., 2012, vol. 64, p. 993.
- Ware, D.C., Siim, B.G., Robinson, K.G., et al., Inorg. Chem., 1991, vol. 30, p. 3750.
- Craig, P.R., Brothers, P.J., Clark, G.R., et al., Dalton Trans., 2004, vol. 4, p. 611.
- Failes, T.W., Cullinane, C., Diakos, C.I., et al., Chem.-Eur. J., 2007, vol. 13, p. 2974.
- Karnthaler-Benbakka, M.S.C., Groza, M.S.D., Kryeziu, M.K., et al., Angew. Chem., Int. Ed. Engl., 2014, vol. 53, p. 12930.
- Palmeira-Mello, M.V., Caballero, A.B., Ribeiro, J.M., et al., J. Inorg. Biochem., 2020, vol. 211, p. 111211.
- Souza, I.S.A., Santana, S.S., Gomez, J.G., et al., Dalton Trans., 2020, vol. 49, p. 16425.
- Khakina, E.A., Nikovskii, I.A., Babakina, D.A., et al., Russ. J. Coord. Chem., 2023, vol. 49, p. 24. https://doi.org/10.1134/S1070328422700105
- Cioncoloni, G., Senn, H.M., Sproules, S., et al., Dalton Trans., 2016, vol. 45, p. 15575.
- Vlcek, A.A., Inorg. Chem., 1967, vol. 6, p. 1425.
- Ma, D.-L., Wu, C., Cheng, S.-S., et al., Int. J. Mol. Sci., 2019, vol. 20, p. 341.
- Sheldrick, G.M., Acta Crystallogr., Sect. A: Found. Crystallogr., 2008, vol. 64, p. 112.
- Dolomanov, O.V., Bourhis, L.J., Gildea, R.J., et al., J. Appl. Crystallogr., 2009, vol. 42, p. 339.
- Stamatatos, T.C., Bell, A., Cooper, P., et al., Inorg. Chem. Commun., 2005, vol. 8, p. 533.
- Alvarez, S., Chem. Rev., 2015, vol. 115, p. 13447.
Қосымша файлдар
